Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.

نویسندگان

  • Stefan H Hohnloser
  • Karl Heinz Kuck
  • Paul Dorian
  • Robin S Roberts
  • John R Hampton
  • Robert Hatala
  • Eric Fain
  • Michael Gent
  • Stuart J Connolly
چکیده

BACKGROUND Implantable cardioverter-defibrillator (ICD) therapy has been shown to improve survival in patients with various heart conditions who are at high risk for ventricular arrhythmias. Whether benefit occurs in patients early after myocardial infarction is unknown. METHODS We conducted the Defibrillator in Acute Myocardial Infarction Trial, a randomized, open-label comparison of ICD therapy (in 332 patients) and no ICD therapy (in 342 patients) 6 to 40 days after a myocardial infarction. We enrolled patients who had reduced left ventricular function (left ventricular ejection fraction, 0.35 or less) and impaired cardiac autonomic function (manifested as depressed heart-rate variability or an elevated average 24-hour heart rate on Holter monitoring). The primary outcome was mortality from any cause. Death from arrhythmia was a predefined secondary outcome. RESULTS During a mean (+/-SD) follow-up period of 30+/-13 months, there was no difference in overall mortality between the two treatment groups: of the 120 patients who died, 62 were in the ICD group and 58 in the control group (hazard ratio for death in the ICD group, 1.08; 95 percent confidence interval, 0.76 to 1.55; P=0.66). There were 12 deaths due to arrhythmia in the ICD group, as compared with 29 in the control group (hazard ratio in the ICD group, 0.42; 95 percent confidence interval, 0.22 to 0.83; P=0.009). In contrast, there were 50 deaths from nonarrhythmic causes in the ICD group and 29 in the control group (hazard ratio in the ICD group, 1.75; 95 percent confidence interval, 1.11 to 2.76; P=0.02). CONCLUSIONS Prophylactic ICD therapy does not reduce overall mortality in high-risk patients who have recently had a myocardial infarction. Although ICD therapy was associated with a reduction in the rate of death due to arrhythmia, that was offset by an increase in the rate of death from nonarrhythmic causes.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Risk Stratification of Sudden Cardiac Death by Evaluating Myocardial Sympathetic Nerve Activity Using Iodine-123 Metaiodobenzylguanidine Scintigraphy in Patients with Chronic Heart Failure and Dilated Cardiomyopathy

A Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) has proven the efficacy of prophylactic implantable cardioverter defibrillator (ICD) use for chronic heart failure pa‐ tients without sustained ventricular tachycardia (SVT) and a history of ventricular fibril‐ lation, not restricted in those with myocardial infarction [1]. Since ICD is an expensive device, risk stratification is required...

متن کامل

THE EFFECT OF NURSE-PEER-LED SUPPORT INTERVENTION ON QUALITY OF LIFE IN PATIENTS WITH AN IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR: A RANDOMIZED CLINICAL TRIAL

Background & Aims: Nowadays, the quality of life and how coping and treatment of patients with an implantable cardiac defibrillator has led to concern and attempts to reduce or eliminate the problems of these patients in the people who provide health care services. This study aimed to determine the effect of nurse-peer-led support intervention on quality of life in patients with an implantable ...

متن کامل

Arrhythmia Risk Stratification after Myocardial Infarction

Summary Post-myocardial infarction ventricular arrhythmia and sudden cardiac death risk remain important issues in these patients. In high-risk post-myocardial infarction (MI) patients prophylactic implantable cardioverter defibrillators (ICD) may significantly improve survival. Risk stratification studies of post-MI patients will allow ICD therapy to be applied in a more cost-effective manner....

متن کامل

Evolution of left ventricular ejection fraction after acute myocardial infarction: implications for implantable cardioverter-defibrillator eligibility.

BACKGROUND Implantable cardioverter-defibrillator therapy improves survival in patients with reduced left ventricular ejection fraction (LVEF) after acute myocardial infarction (AMI). Although the risk of sudden cardiac death is highest in the first month after AMI, there is no survival benefit of early implantable cardioverter-defibrillator implantation, and the optimal time frame has yet to b...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • The New England journal of medicine

دوره 351 24  شماره 

صفحات  -

تاریخ انتشار 2004